ASH 2020 | The BYOND trial: bosutinib shows promise in heavily pre-treated CML patients

Andreas Hochhaus • 27 Nov 2020

ASH 2020

BYOND

Andreas Hochhaus, MD, Klinik für Innere Medizin II, Jena, Germany, discusses the results of BYOND (NCT02228382), a Phase IV study aiming to assess the efficacy and safety of bosutinib, a second-generation tyrosine kinase inhibitor (TKI), in heavily pre-treated chronic myeloid leukemia (CML) patients. In previous studies starting with high doses of bosutinib, toxicities such as diarrhea were a major issue. In this study, however, a titration-based therapy supported with anti-diarrheal medication was able to yield response rates higher than initially expected. While it is currently registered as a frontline treatment, these findings suggest that bosutinib is an excellent candidate for previously treated CML patients. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.